We report a response to pazopanib in a 69-year-old man with heavily pre-treated 
metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his 
tumor. To our knowledge, this case is the earliest to demonstrate activity of an 
oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides 
rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of 
regorafenib, another multi-targeted kinase inhibitor, in patients with 
liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This 
national multi-institutional study is ongoing.